PROSTATE CANCER AR splice variant dimerization-clinical implications

被引：12

作者：

Antonarakis, Emmanuel S. ^{[1
]}

Luo, Jun ^{[2
]}

机构：

[1] Johns Hopkins Univ, Sch Med, Dept Oncol, Baltimore, MD 21287 USA

[2] Johns Hopkins Univ, Sch Med, Dept Urol, Baltimore, MD 21287 USA

来源：

NATURE REVIEWS UROLOGY | 2015年 / 12卷 / 08期

关键词：

RECEPTOR; RESISTANCE;

D O I：

10.1038/nrurol.2015.184

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

100201 [内科学]; 100221 [泌尿外科学];

摘要：

Androgen receptor splice variants might be associated with castration resistance in prostate cancer as well as resistance to hormonal therapies including abiraterone and enzalutamide. New data demonstrate that splice variants can form dimers with each other as well as with the full-length androgen receptor, and that dimerization is required for androgen-independent transcriptional activation of target genes.

引用

页码：431 / 433

页数：3

共 10 条

[1]

Antonarakis E S., JAMA Oncol

[2]

AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer [J].

Antonarakis, Emmanuel S. ;

Lu, Changxue ;

Wang, Hao ;

Luber, Brandon ;

Nakazawa, Mary ;

Roeser, Jeffrey C. ;

Chen, Yan ;

Mohammad, Tabrez A. ;

Chen, Yidong ;

Fedor, Helen L. ;

Lotan, Tamara L. ;

Zheng, Qizhi ;

De Marzo, Angelo M. ;

Isaacs, John T. ;

Isaacs, William B. ;

Nadal, Rosa ;

Paller, Channing J. ;

Denmeade, Samuel R. ;

Carducci, Michael A. ;

Eisenberger, Mario A. ;

Luo, Jun .

NEW ENGLAND JOURNAL OF MEDICINE, 2014, 371 (11) :1028-1038

[3]

Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer [J].

Asangani, Irfan A. ;

Dommeti, Vijaya L. ;

Wang, Xiaoju ;

Malik, Rohit ;

Cieslik, Marcin ;

Yang, Rendong ;

Escara-Wilke, June ;

Wilder-Romans, Kari ;

Dhanireddy, Sudheer ;

Engelke, Carl ;

Iyer, Mathew K. ;

Jing, Xiaojun ;

Wu, Yi-Mi ;

Cao, Xuhong ;

Qin, Zhaohui S. ;

Wang, Shaomeng ;

Feng, Felix Y. ;

Chinnaiyan, Arul M. .

NATURE, 2014, 510 (7504) :278-+

[4]

Androgen receptor splice variants activating the full-length receptor in mediating resistance to androgen-directed therapy [J].

Cao, Bo ;

Qi, Yanfeng ;

Zhang, Guanyi ;

Xu, Duo ;

Zhan, Yang ;

Alvarez, Xavier ;

Guo, Zhiyong ;

Fu, Xueqi ;

Plymate, Stephen R. ;

Sartor, Oliver ;

Zhang, Haitao ;

Dong, Yan .

ONCOTARGET, 2014, 5 (06) :1646-1656

[5]

An androgen receptor N-terminal domain antagonist for treating prostate cancer [J].

Myung, Jae-Kyung ;

Banuelos, Carmen A. ;

Fernandez, Javier Garcia ;

Mawji, Nasrin R. ;

Wang, Jun ;

Tien, Amy H. ;

Yang, Yu Chi ;

Tavakoli, Iran ;

Haile, Simon ;

Watt, Kate ;

McEwan, Iain J. ;

Plymate, Stephen ;

Andersen, Raymond J. ;

Sadar, Marianne D. .

JOURNAL OF CLINICAL INVESTIGATION, 2013, 123 (07) :2948-2960

[6]

Systematic Structure Modifications of Multitarget Prostate Cancer Drug Candidate Galeterone To Produce Novel Androgen Receptor Down-Regulating Agents-as an Approach to Treatment of Advanced Prostate Cancer [J].

Purushottamachar, Puranik ;

Godbole, Abhijit M. ;

Gediya, Lalji K. ;

Martin, Marlena S. ;

Vasaitis, Tadas S. ;

Kwegyir-Afful, Andrew K. ;

Ramalingam, Senthilmurugan ;

Ates-Alagoz, Zeynep ;

Njar, Vincent C. O. .

JOURNAL OF MEDICINAL CHEMISTRY, 2013, 56 (12) :4880-4898

[7]

Steinestel J, ONCOTARGET IN PRESS

[8]

Tepper CG, 2002, CANCER RES, V62, P6606

[9]

Xu D, CANC RES

[10]

lncRNA-dependent mechanisms of androgen-receptor-regulated gene activation programs [J].

Yang, Liuqing ;

Lin, Chunru ;

Jin, Chunyu ;

Yang, Joy C. ;

Tanasa, Bogdan ;

Li, Wenbo ;

Merkurjev, Daria ;

Ohgi, Kenneth A. ;

Meng, Da ;

Zhang, Jie ;

Evans, Christopher P. ;

Rosenfeld, Michael G. .

NATURE, 2013, 500 (7464) :598-+

← 1 →